Worth reading
40Recurring
Scored from 4 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
55.6
Year-on-year change in operating profit (%)Wording
Definitive
How definitive the wording is.Results for this period
Interim period (second quarter)2024年4月1日〜2024年9月30日ConsolidatedJapanese GAAPNet Sales27,957¥ millionYear on year +3.2%
Operating profit2,183¥ millionYear on year +55.6%
Ordinary income2,233¥ millionYear on year +34.9%
Net income attributable to owners of the parent1,468¥ millionYear on year +30.3%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Financial position at period-end
Total assets83,908¥ million
of which net assets 59,601 ¥ million
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Cash inflows and outflows
Operating+2,937
Investment-1,436
Financials-2,031
Net change-530
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥13,741 million
Segment revenue
Functional Materials Business14,80353.0%+6.5%
Electronic materials and chemicals business12,59445.0%+0.1%
Other5592.0%-8.5%
Segment profit
Functional Materials Business1,12451.5%
Electronic materials and chemicals business93642.9%
Other1235.6%
Outlook and shareholder returns
Full-year earnings forecast
Net SalesNot disclosed
Operating profitNot disclosed
Ordinary incomeNot disclosed
Net incomeNot disclosed
Remarks2024年5月10日公表の業績予想から変更なし
Factors Behind Changes in Business Performance
化粧品向け機能性微粒子製品の販売好調、車載用コンデンサ向け導電性高分子薬剤の販売伸長、販売価格改定、化粧品原料向け販売の回復など
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Impairment lossNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income No applicable matters. / Extraordinary loss Item Loss on Disposal of Fixed Assets / Amount ¥76 million
Depreciation and amortization¥1,320 million
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年4月1日〜2024年9月30日 |
| Net Sales | ¥27,957 million (YoY +3.2%) |
| Operating profit | ¥2,183 million (YoY +55.6%) |
| Ordinary income | ¥2,233 million (YoY +34.9%) |
| Profit attributable to owners of the parent | ¥1,468 million (YoY +30.3%) |
| Total assets | ¥83,908 million |
| Net assets | ¥59,601 million |
| Cash flows from operating activities | ¥2,937 million |
| Cash flows from investing activities | ¥-1,436 million |
| Cash flows from financing activities | ¥-2,031 million |
| Cash and cash equivalents at end of period | ¥13,741 million |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Remarks 2024年5月10日公表の業績予想から変更なし |
| Segment revenue | Functional Materials Business ¥14,803 million (YoY +6.5%) / Electronic materials and chemicals business ¥12,594 million (YoY +0.1%) / Other ¥559 million (YoY -8.5%) |
| Segment profit | Functional Materials Business ¥1,124 million / Electronic materials and chemicals business ¥936 million / Other ¥123 million |
| Depreciation and amortization | ¥1,320 million |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income No applicable matters. / Extraordinary loss Item Loss on Disposal of Fixed Assets / Amount ¥76 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Factors Behind Changes in Business Performance | 化粧品向け機能性微粒子製品の販売好調、車載用コンデンサ向け導電性高分子薬剤の販売伸長、販売価格改定、化粧品原料向け販売の回復など |
Items this document does not state (15)
Net income per shareOperating MarginEquity ratioRevision to Earnings ForecastAnnual Dividend ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.化粧品向け機能性微粒子製品の販売が好調であったこと、車載用コンデンサ向け導電性高分子薬剤の販売が伸長したことなどによる。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.